Sign In
Buy AFMD
$0.182
+0 (+0%)
At Close: Sep 16, 2025
Affimed Announces 1-for-10 Reverse Stock Split
06:30am, Wednesday, 06'th Mar 2024
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
04:05pm, Monday, 08'th Jan 2024
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
Affimed Announces Leadership Change and Organizational Restructuring
08:00am, Monday, 08'th Jan 2024
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
06:30am, Wednesday, 03'rd Jan 2024
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
3 Penny Stocks That Are Too Compelling to Ignore
09:08am, Tuesday, 19'th Dec 2023
While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors shy away f
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
06:30am, Monday, 04'th Dec 2023
MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back the
Affimed N.V. (AFMD) Q3 2023 Earnings Call Transcript
01:57pm, Tuesday, 14'th Nov 2023
Affimed N.V. (NASDAQ:AFMD ) Q3 2023 Results Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Alexander Fudukidis - Director and Head of Investor Relations Adi Hoess - Chief E
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
06:30am, Tuesday, 07'th Nov 2023
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou
Affimed to Participate in Upcoming Investor Conferences
06:30am, Wednesday, 01'st Nov 2023
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their
Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround
11:22am, Wednesday, 25'th Oct 2023
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Affimed to Present at the Cantor Global Healthcare Conference 2023
06:30am, Thursday, 21'st Sep 2023
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back thei
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
06:30am, Thursday, 07'th Sep 2023
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, an
Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.
06:00am, Wednesday, 23'rd Aug 2023
Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, the concept of top Wall Street penny stocks is not
